Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods

• US 8,425,921 B1
• Filed: 09/26/2011
• Issued: 04/23/2013
• Est. Priority Date: 05/18/2007
• Status: Active Grant

• Current Assignee: Heidi Kay
• Original Assignee: Heidi Kay
• Inventors: Kay, Heidi
• Primary Examiner(s): NAZARIO GONZALEZ, PORFIRIO
• Application Number:
  US13/245,279
• Time in Patent Office: 575 Days
• Field of Search: 556/137, 514/492, 424/278.1
• US Class Current: 424/278.1
• CPC Class Codes: A61K 31/282 Platinum compounds
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: C07F 15/0093 without a metal-carbon linkage

Abstract

The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders.

Claims

1. A method for reducing matrix metalloproteinases (MMP) in a patient in need thereof, the method comprising administering an effective amount of a platinum(IV) compound effective for reducing the MMP to the patient, the platinum (IV) compound comprising the structure shown in at least one of formula (II) or (IV):

2. The method of claim 1, wherein X and Y are independently selected from the group consisting of F, CI, Br, and I;

R¹ is —

NO₂;

R² is Cl; and

R³ is —

NH₃.

3. The method of claim 2, wherein X and Y are Cl.

5. The method of claim 1, wherein the matrix metalloproteinase is at least one of MT MMP 1, MMP 2, or MMP 9.

8. The method of claim 5, wherein X and Y are independently selected from the group consisting of F, Cl, Br, and I;

R¹ is —

NO₂;

R² is Cl; and

R³ is —

NH₃.

9. The method of claim 8, wherein X and Y are Cl.

4. A method for reducing matrix metalloproteinases (MMP) in a patient in need thereof, the method comprising administering an effective amount of a platinum(IV) compound effective for reducing MMP to the patient, the platinum(IV) compound comprising the structure shown in at least one of formula (II) or (IV):

6. The method of claim 4, wherein the matrix metalloproteinase is at least one of MT MMP 1, MMP 2, or MMP 9.

7. A method for reducing matrix metalloproteinases (MMP) in a patient in need thereof, the method comprising administering an effective amount of a platinum (IV) compound effective for reducing the MMP to the patient, the platinum (IV) compound comprising the structure shown in at least one of formula (I) or (III):

10. The method of claim 7, wherein the matrix metalloproteinase is at least one of MT MMP 1, MMP 2, or MMP 9.

11. A method for reducing matrix metalloproteinases (MMP) in a patient in need thereof, the method comprising administering an effective amount of a platinum(IV) compound effective for reducing MMP to the patient, the platinum(IV) compound comprising the structure shown in at least one of formula I or III:

12. The method of claim 11, wherein the matrix metalloproteinase is at least one of MT MMP 1, MMP 2, or MMP 9.